Ephedra hearings
This article was originally published in The Tan Sheet
Executive Summary
House Energy & Commerce Committee/Subcommittee on Oversight & Investigations plans second day of hearings on botanical July 24, following previously-announced July 23 session (1"The Tan Sheet" July 14, 2003, In Brief). Hearings will take place in room 2123 in the Rayburn office building...
You may also be interested in...
Metabolife execs subpoenaed
House Energy & Commerce Subcommittee on Oversight & Investigations authorizes issuance of three subpoenas to former and current Metabolife employees in 9-0 vote. During business meeting held July 10, Rep. Greg Walden (R-Ore.) noted that in response to hearing invitation letters sent to 13 individuals, three Metabolife witnesses "have sent written responses through their respective counsels declining the invitation to testify." Founder, co-owner and former president Michael Ellis, former president David Brown and current employee Daniel Rodriguez will be issued subpoenas "as quickly as possible," committee says. In response, Metabolife maintains it is cooperating with House investigation and "looks forward to having its senior officials, including" CEO Russell Schreck, testify. First of two hearings on ephedra is scheduled for July 23; House inquiry began in February (1"The Tan Sheet" March 3, 2003, p. 9)...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.